BioCentury on BioBusiness, Politics and Policy
Diagnostic methods patents more vulnerable after Myriad gene patent decision
Patently vulnerable
By Aaron Bouchie
Senior Writer
Published on Monday, August 8, 2011
Molecular diagnostics companies
will have to include a machine or transformative step in their patent claims
based on the ruling by the Court of Appeals for the Federal Circuit in the
Myriad Genetics case. The likely result will be a narrowing of claims, which
will make MDx tests more vulnerable to competition.
The CAFC ruled that Myriad
Genetics Inc.'s method claims for analyzing the breast cancer 1 early
onset (BRCA1) and BRCA2 genes were invalid, although the court did uphold the
patents on the genes themselves.
86 words displayed of 1058 words total.
Get the Full Text...
All contents Copyright © 1993-2012 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Purchase This Article
Learn what you're missing.
Broaden your Knowledge Base
The BioCentury Publications Package provides the essential coverage and analysis required by global biopharma decision makers.
Take advantage of our free trials and discover why BioCentury is the choice of biopharma professionals around the globe.
Free Trials Begin the Week Following Sign-up
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your records.
close [ X ]